Results 61 to 70 of about 1,824,517 (243)
Antibody-based immunosuppressive agents for corneal transplantation
, 2009 The progress in antibody engineering over the last 20 years has created the tools for the development of novel antibody-based drugs and constructs, such as small antibody fragments, suitable for topical administration.
Thiel, M A +11 more
core +1 more source
Chronobiology of Cancer: How Aging Fuels Oncogenesis at the Molecular Level
Aging and Cancer, EarlyView.This graphical abstract illustrates the key biological pathways linking aging with cancer development and progression. In the upper left, cumulative exposure to ultraviolet radiation, toxins, and reactive oxygen species (ROS) causes DNA damage and genomic instability, whereas age‐related decline in repair mechanisms, such as ATM/ATR, BER, and NER ...
Anu Singh, Aroonima Misra, Sufian Zaheer
wiley +1 more source
, 2013 Hidradenitis suppurativa (HS) is a difficult disease to treat. Although the pathogenesis of this inflammatory skin disease is largely unknown, the important role of the immune system has been demonstrated in both experimental and clinical studies ...
Horvath, B. +8 more
core +1 more source
, 2020 Number of liver and kidney transplantation patients who used immunosuppressive agents at 1,4, and 12 months, split by having hyperglycemia (HG) or not at each follow-up.
K. Tuesday Werner (8282205) +4 more
core +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan +5 more
wiley +1 more source
Effect of Immunosuppressive Agents on Hepatocyte Apoptosis Post-Liver Transplantation. [PDF]
PLoS ONE, 2015 Immunosuppressants are used ubiquitously post-liver transplantation to prevent allograft rejection. However their effects on hepatocytes are unknown. Experimental data from non-liver cells indicate that immunosuppressants may promote cell death thereby ...
Eu Jin Lim +6 more
doaj +1 more source
Development of Non-Immunosuppressive FK506 Derivatives as Antifungal and Neurotrophic Agents
, 2021 FK506, also known as tacrolimus, is a clinically important immunosuppressant drug and has promising therapeutic potentials owing to its antifungal, neuroprotective, and neuroregenerative activities. To generate various FK506 derivatives, the structure of
윤여준
core +1 more source
Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin +11 more
wiley +1 more source
, 2015 Data are shown as median (range in parenthesis); EGPA: eosinophilic granulomatosis with polyangiitis (Churg-Strauss); immunosuppr., immunosuppressive agents (9 patients were on methotrexate, 7 on azathioprine and 1 on mycophenolate mofetil); LR, Logistic
David Cuthbertson (188652) +14 more
core +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background Factors associated with relapse course and disability in myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD) remain incompletely understood. Objectives To identify clinical and modifiable factors associated with relapse and disability in MOGAD. Methods In this ambispective multicentre cohort study using data from
Yingtao Wang +23 more
wiley +1 more source